Literature DB >> 2792966

Metabolism of 2-amino-3-methylimidazo[4,5-f]quinoline in the male rat.

T Inamasu1, H Luks, M T Vavrek, J H Weisburger.   

Abstract

The metabolism of 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) was studied in the male rat using the radiochemical labels 14C and 3H at positions 2 and 5 of the molecule, respectively. Adult male Fischer 344 rats were administered [2-14C]IQ or [5-3H]IQ by oral gavage at dose levels of 20 or 40 mg/kg body weight. Rats were also given [2-14C]IQ in the diet at a dose level of 300 ppm for 2 days and after administration of unlabelled IQ (300 ppm) in the diet for approximately 6.5 wk for an additional 2 days. In the initial 48 hr following oral administration of 20 or 40 mg [2-14C]IQ/kg body weight, about 40-50% radioactivity was recovered in the urine, and about 30-38% radioactivity was recovered in the faeces. In the initial 72 hr following consumption of [2-14C]IQ (300 ppm) in the diet about 26% radioactivity was recovered in the urine and about 61% radioactivity was recovered in the faeces. Following cannulation of the bile ducts, rats administered a single dose of [2-14C]IQ (40 mg/kg body weight) by oral gavage excreted about 15% of the administered dose in the bile over a period of 2 days. Urine from rats given [2-14C]IQ contained three main polar metabolites that included a glucuronide, a sulphate ester and IQ sulphamate, and a number of less polar metabolites that included IQ, 2-acetylamino-3-methylimidazo[4,5-f]quinoline, 2-aminoimidazo[4,5-f]quinoline and 2-amino-3,6-dihydro-3-methyl-7H-imidazo[4,5-f]quinoline-7-one (7-OH-IQ). Administration of [2-14C]IQ by oral gavage or in the diet gave the same metabolites, but in different amounts. In the faeces of rats given [2-14C] by oral gavage, IQ-sulphamate was the major metabolite in the polar fraction. Non-polar metabolites similar to those found in the urine were also present, but in different amounts. A major, non-polar faecal metabolite, 7-OH-IQ was probably formed as a result of the activity of the intestinal bacterial flora. In rats given a single gavage dose of [2-14C]IQ, excretion of metabolites was higher in the urine and lower in the faeces compared with that in animals fed [2-14C]IQ in the diet. One polar metabolite present in the urine, IQ-sulphamate (39%), was found at considerably higher levels in rats dosed orally with IQ compared with those fed IQ (less than 6%). Thus, IQ is extensively metabolized to give a number of polar and non-polar metabolites, the amounts of which depend, in part, on the mode of dosing.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2792966     DOI: 10.1016/0278-6915(89)90142-7

Source DB:  PubMed          Journal:  Food Chem Toxicol        ISSN: 0278-6915            Impact factor:   6.023


  5 in total

1.  Characterization of new metabolites from in vivo biotransformation of 2-amino-3-methylimidazo[4,5-f]quinoline in mouse by mass spectrometry.

Authors:  Fong-Fu Hsu; Vijaya M Lakshmi; Terry V Zenser
Journal:  J Mass Spectrom       Date:  2009-09       Impact factor: 1.982

2.  N-Demethylation is a major route of 2-amino-3-methylimidazo[4,5-f]quinoline metabolism in mouse.

Authors:  Vijaya M Lakshmi; Fong Fu Hsu; Terry V Zenser
Journal:  Drug Metab Dispos       Date:  2008-03-20       Impact factor: 3.922

3.  Identification of new 2-amino-3-methylimidazo[4,5-f]quinoline urinary metabolites from beta-naphthoflavone-treated mice.

Authors:  Vijaya M Lakshmi; Fong-Fu Hsu; Terry V Zenser
Journal:  Drug Metab Dispos       Date:  2009-05-18       Impact factor: 3.922

4.  Dietary modulation of DNA adduct formation of the food mutagen 2-amino-3-methylimidazo[4,5-f]quinoline in the male Fischer 344 rat.

Authors:  H A Schut
Journal:  Environ Health Perspect       Date:  1994-10       Impact factor: 9.031

5.  Formation of 2-amino-3-methylimidazo[4,5-f]quinoline- and 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline-sulfamates by cDNA-expressed mammalian phenol sulfotransferases.

Authors:  S Ozawa; K Nagata; Y Yamazoe; R Kato
Journal:  Jpn J Cancer Res       Date:  1995-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.